BioLineRx (BLRX) Share-based Compensation (IS) (2014 - 2025)
BioLineRx (BLRX) recorded quarterly Share-based Compensation (IS) of $48000.0 in Q4 2025, down 52.48% quarter-over-quarter from $101000.0 in Q3 2025, and up 131.17% on a YoY basis from $20764.0 in Q4 2024.
BioLineRx (BLRX) Share-based Compensation (IS) (2014 - 2025) Analysis & Trends
BioLineRx's Share-based Compensation (IS) history runs 12 years deep, the most recent figure standing at $48000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation (IS) rose 131.17% year-over-year to $48000.0; the TTM figure through Dec 2025 stood at $396000.0 (down 65.11% YoY), while the FY2025 annual figure was $396000.0, down 65.11% from the prior year.
- Share-based Compensation (IS) was $48000.0 for Q4 2025 at BioLineRx, down from $101000.0 in the prior quarter.
- In the past five years, Share-based Compensation (IS) ranged from a high of $1.0 million in Q4 2022 to a low of -$154000.0 in Q4 2024.
- Historically, Share-based Compensation (IS) has averaged $379600.0 across 5 years, with a median of $376000.0 in 2021.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation (IS) surged 167.26% in 2022, then slumped 116.58% in 2024.
- A 5-year view of Share-based Compensation (IS) shows it stood at $391000.0 in 2021, then soared by 167.26% to $1.0 million in 2022, then decreased by 11.1% to $929000.0 in 2023, then plunged by 116.58% to -$154000.0 in 2024, then soared by 131.17% to $48000.0 in 2025.
- The last three Share-based Compensation (IS) figures came in at $48000.0 (Q4 2025), $101000.0 (Q3 2025), and $53000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.45 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 892,057.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 14.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | 48,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 48,000.00 |
| Dec 31, 2025 | 48,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Sep 30, 2023 | 472,000.00 |